{"topic_id":"eu_ema_qa_alimentary_pet","category":"eu-2026-approvals","context":"---\ntopic_id: eu_ema_qa_alimentary_pet\ncategory: eu-2026-approvals\ntitle: \"EU EMA Veterinary Medicines: QA Alimentary Tract — SGLT2 Inhibitors for Diabetes and Obesity in Dogs, Cats and Horses\"\nlang: en\nsource: \"ema-medicines-report.xlsx\"\ndate_parsed: \"2026-07-21\"\ntokens_estimated: 320\nverification:\n  method: substring_match\n  claims: 5\n  passed: 5\n  date: \"2026-07-21\"\n---\n\n## Overview\n\nThe ATCvet **QA** category covers the alimentary tract and metabolism. Within the EMA Union Product Database (medicines-output-medicines-report, generated 20/07/2026), the pet-relevant QA medicines are concentrated in two pharmacological groups: **SGLT2 inhibitors for diabetes** (QA10) and **antiobesity preparations** (QA08). All are **Veterinary** category (`Category = \"Veterinary\"`) with EMA product numbers prefixed `EMEA/V/C/`.\n\n## SGLT2 Inhibitors: Canine and Feline Diabetes\n\n### Bexatil (bexagliflozin) — EMEA/V/C/006300\n\n- **INN**: Bexagliflozin (INN: bexagliflozin)\n- **Active substance**: bexagliflozin\n- **Species**: Cats\n- **Status**: Opinion\n- **Pharmacotherapeutic group**: Drugs used in diabetes\n- **Indication**: For the treatment of cats newly diagnosed with diabetes mellitus to reduce hyperglycaemia and to improve hyperglycaemia-associated clinical signs\n- **Marketing authorisation holder**: Elanco GmbH\n\n### Scovella (velagliflozin) — EMEA/V/C/006610\n\n- **INN**: Velagliflozin (INN: velagliflozin)\n- **Active substance**: velagliflozin\n- **Species**: Horses\n- **Status**: Opinion\n- **Pharmacotherapeutic group**: Drugs used in diabetes\n- **Indication**: For the treatment of hyperinsulinaemia and associated clinical signs (e.g., laminitis) in insulin-dysregulated horses and ponies\n- **Marketing authorisation holder**: Boehringer Ingelheim Vetmedica GmbH\n\n### Note on ATCvet Code\n\nBoth products carry ATCvet code **QA10BK90** — the \"BK90\" suffix indicates \"other blood glucose lowering drugs, excl. insulins,\" a subcategory of QA10 (drugs used in diabetes).\n\n## Antiobesity Preparations for Dogs\n\n### Slentrol (dirlotapide) — EMEA/V/C/000116\n\n- **INN**: Dirlotapide (INN: dirlotapide)\n- **ATCvet code**: QA08AB91\n- **Species**: Dogs\n- **Status**: Withdrawn\n- **Pharmacotherapeutic group**: Antiobesity preparations, excl. diet products\n- **Indication**: As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight-management programme including dietary restriction and increased physical activity\n- **Marketing authorisation holder**: Zoetis Belgium SA\n\n### Yarvitan (mitratapide) — EMEA/V/C/000113\n\n- **INN**: Mitratapide (INN: mitratapide)\n- **ATCvet code**: QA08AB90\n- **Species**: Dogs\n- **Status**: Withdrawn\n- **Pharmacotherapeutic group**: Antiobesity preparations, excl. diet products\n- **Indication**: As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight management programme\n- **Marketing authorisation holder**: Janssen Pharmaceutica N.V.\n\n## Microvascular/Bone Morphogenetic Protein\n\n### TruScient (dibotermin alfa) — EMEA/V/C/002000\n\n- **INN**: Dibotermin alfa (INN: dibotermin alfa)\n- **ATCvet code**: QM05BC01\n- **Species**: Dogs\n- **Status**: Withdrawn\n- **Pharmacotherapeutic group**: Bone morphogenetic proteins\n- **Indication**: Osteoinductive agent for use in the treatment of long-bone fractures as an adjunct to standard surgical care using open reduction and internal fixation techniques\n- **Marketing authorisation holder**: Zoetis Belgium SA\n\nNote: Although QM05BC01 is musculo-skeletal (QM05), it is listed in the QA alimentary tract data and appears in the QA-related product family.\n\n## Summary Table\n\n| Product | INN | Species | ATCvet | Status | Indication |\n|---|---|---|---|---|---|\n| Bexatil | bexagliflozin | Cats | QA10BK90 | Opinion | Feline diabetes mellitus |\n| Scovella | velagliflozin | Horses | QA10BK90 | Opinion | Hyperinsulinaemia/laminitis in horses |\n| Slentrol | dirlotapide | Dogs | QA08AB91 | Withdrawn | Canine obesity management |\n| Yarvitan | mitratapide | Dogs | QA08AB90 | Withdrawn | Canine obesity management |\n\nSource: EMA medicines-output-medicines-report_en.xlsx, dataset generated 20/07/2026 - 18:00, accessed via `https://www.ema.europa.eu/en/medicines/download-medicine-data`.\n","sources":[],"tokens_estimated":320,"generated_at":null,"tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}